Introduction
Multiple randomized trials have demonstrated the advantages of mobilized peripheral blood over bone marrow as the stem cell source for autologous transplantation. [1] [2] [3] These features include shorter duration of cytopenias, enhanced immune reconstitution and reduced morbidity. Consequently, peripheral blood stem cells (PBSCs) currently are the primary source of stem cells for autologous transplantation worldwide. 4 Despite the clear benefit of PBSCs in the autologous transplant setting, enthusiasm for the use of PBSC in allogeneic transplantation was initially tempered by concerns that the 10-to 50-fold increase in the T-cell content of mobilized peripheral blood would lead to unacceptable rates of graft-versus-host disease (GVHD). However, studies comparing granulocyte colony stimulating factor (G-CSF) mobilized PBSCs to bone marrow in human leukocyte antigen (HLA)-matched sibling allografts have demonstrated that PBSCs are associated with more rapid engraftment, reduction of infectious complications and, in patients with advanced hematologic malignancies, a lower regimen-related mortality. [5] [6] [7] The rate of acute GVHD appears to be similar with either stem cell source, but more chronic GVHD is observed with mobilized peripheral blood. [8] [9] [10] In many centers, mobilized peripheral blood is now the preferred stem cell source for HLAidentical sibling transplantation. 4 PBSCs are increasingly used for volunteer unrelated transplants as well.
Currently, only G-CSF and granulocyte-macrophage colony stimulating factor (GM-CSF) are Food and Drug Administration (FDA) approved for the mobilization of autologous stem cells, and G-CSF is the predominant mobilizing agent used in the allogeneic setting. However, G-CSF-based mobilization requires 4-6 days of treatment and is associated with some morbidity and rare serious complications. In this review, we will discuss alternative mobilizing approaches, which may improve the efficiency and outcome of allogeneic stem cell collection and transplantation. We will focus on adult recipients, as recent data suggest outcomes in certain clinical situations (e.g. aplastic anemia, low risk leukemia) may be worse in pediatric recipients of allogeneic PBSC in comparison to bone marrow allografts. adhesion molecules, including lymphocyte function-associated antigen-1, very late antigen-4 (VLA-4), CXCR4, c-kit, CD44 and Mac-1, are known to tether stem cells to the bone marrow microenvironment, and disruption of the interactions between these adhesion molecules and their ligands by cytokines may promote stem and progenitor cell egress into the peripheral circulation. For instance, hematopoietic progenitor cells (HPCs) are mobilized after exposure to antibodies which interrupt the interaction of the b1 integrin VLA-4, expressed on HPCs, and its ligand, vascular cell adhesion molecule-1 (VCAM-1), expressed on endothelial and stromal cells. 12, 13 Chemokines have recently emerged as key regulators of HPC mobilization, particularly members of the CXC chemokine family, including stromal-derived factor-1 (SDF-1, also known as CXCL-12), and GROb. The chemokine SDF-1 is constitutively expressed by bone marrow stromal cells, and its receptor CXCR4 is a transmembrane G-protein-coupled receptor expressed on CD34 þ cells. Interaction between SDF-1 and CXCR4 critically regulates migration of bone marrow, umbilical cord blood, and G-CSF mobilized peripheral blood cells transplanted into non-obese diabetic/severe combined immunodeficient (NOD/SCID) mice, 14 and neutralizing antibodies to CXCR4 or SDF-1 significantly reduce HPC homing, migration and mobilization. 15 As discussed below, a direct inhibitor of the SDF-1/CXCR4 interaction, AMD3100, is an effective mobilizing agent currently being tested in clinical trials.
Binding of the chemokine GROb to its receptor CXCR2 also plays an important role in stem cell localization in bone marrow. The N-terminal truncated variant of GROb, SB-251353 (GROb-T) can rapidly mobilize HPCs in mice and monkeys, an effect that is enhanced by combination with G-CSF. A single injection of SB-251353 combined with 4 days of G-CSF results in fivefold greater HPC mobilization than G-CSF alone. 16, 17 These promising results in animal models suggest that the efficacy of SB-251353 for stem cell mobilization might be exploited clinically if this agent was well tolerated.
The mechanisms by which cytokines trigger stem cell mobilization remain incompletely understood. Liu et al. 18 have shown that G-CSF receptor expression is not required on HPCs for their mobilization by G-CSF, suggesting that G-CSF acts indirectly on HPCs. Proteases have been implicated as the secondary signals, which lead to HPC mobilization induced by G-CSF. G-CSF may activate neutrophils and other target cells, leading to release of proteases which cleave the adhesive interactions between HPCs and the bone marrow microenvironment. 19, 20 In support of this model, Levesque et al. 21 identified two serine proteases, neutrophil elastase and cathepsin G, which increase in concentration during G-CSF mobilization and are directly able to cleave VCAM-1. In addition, the activity of IL-8, a CXC chemokine that induces rapid mobilization of HPCs, 22 appears to be mediated by neutrophil activation and subsequent release of matrix metalloproteinase-9 (MMP-9). 23 In rhesus monkeys, IL-8-induced mobilization is completely inhibited by antibodies that block MMP-9 activity. 24 GROb-induced mobilization also may be mediated by MMP-9. 16, 25 Regulation of the SDF-1/CXCR4 interaction may occur via proteolytic cleavage of SDF-1 or CXCR4. 15, 19, 26 Recent evidence has identified CD26, a membrane-bound extracellular peptidase, as the prime protease that cleaves SDF-1 within the bone marrow. 27 Of note, G-CSF-induced mobilization is inhibited in mice deficient in CD26. 28 Despite this evidence, important studies in proteasedeficient mice contradict a central role for proteases in cytokine-induced stem cell mobilization. Three studies have shown that MMP-9-deficient mice have a similar increase in peripheral HPCs following treatment with IL-8 or G-CSF as wild-type mice. 25, 29, 30 Similarly, HPC mobilization with IL-8 or G-CSF was intact in neutrophil elastase-cathepsin G-deficient mice, and SDF-1 protein levels were decreased in the protease-deficient mice, as is observed in wild-type mice. 29 These studies suggest that non-proteolytic mechanisms may play a fundamental role in stem cell mobilization. One likely mechanism is transcriptional regulation. Semerad et al. 31 have found that SDF-1 mRNA in bone marrow cells is significantly reduced during G-CSF mobilization, suggesting that SDF-1 expression is regulated at the mRNA level.
Recent studies have shed light on another pathway in which G-CSF may indirectly exert its effects on SDF-1/ CXCR4 signaling. UDP-galactose ceramide galactosyltransferase-deficient (Cgt(À/À)) mice exhibit aberrant nerve conduction and display virtually no PBSC egress from BM following G-CSF or fucoidan administration. Using mice lacking Cgt, a known neurotransmitter, Katayama et al. 32 demonstrated that G-CSF-dependent stem cell mobilization may be governed by neural signals such as those transmitted by norepinephrine. Stem cell mobilization was deficient in mice lacking Cgt, and could also be diminished using beta-blockers. Beta adrenergic drugs, on the other hand, stimulated mobilization. These data suggest a heretofore unknown neural control over stem cell trafficking and raise the intriguing possibility that currently available agents (e.g. beta agonists) may be exploited to enhance mobilization in certain subsets of patients.
Targeting of the stem cell niche by G-CSF may induce stem cell mobilization
The hematopoietic stem cell niche is a complex multidimensional environment where HPC communicate with a variety of supporting elements such as osteoblasts, endothelial cells and extracellular matrix, which collectively sustain stem cell function. Osteoblasts in particular have been shown to provide critical signals (e.g. via notch) that can either maintain stem cell quiescence or direct selfrenewal, differentiation or both. Until recently, osteoclasts (OCLs) were not recognized to have an important role in regulating stem cell behavior, including mobilization. However, Kollet et al. 33 recently demonstrated that specific stimulation of OCLs with receptor activator of nuclear factor kB ligand (RANKL) recruited immature progenitors to the circulation in a CXCR4-and MMP-9-dependent manner. RANKL did not induce mobilization in mice with defective OCL bone adhesion and resorption. Inhibition of OCLs with calcitonin reduced progenitor egress during homeostasis, and following G-CSF stimulation. RANKLstimulated bone-resorbing OCLs also reduced the stem cell niche components SDF-1, stem cell factor and osteopontin, which were associated with progenitor mobilization. These findings indicate a potential involvement of OCLs in selective progenitor recruitment as part of homeostasis and host defense. OCLs may therefore be an important mediator of mobilization induced by G-CSF and other cytokines, creating a possible link between bone remodeling and regulation of hematopoiesis.
Taken together, recent insights clearly implicate the CXCR4/SDF-1 pathway as a critical determinant of HSC/ HPC mobilization. This interaction therefore is a logical target for manipulations designed to enhance mobilization or, conversely, improve homing of transplanted cells back into the hematopoietic microenvironment. A more complete understanding of the interactions between HPCs and the bone marrow microenvironment is needed to identify additional targets for the stimulation of HPC mobilization.
What is the optimal allograft content?
The number and function of various cellular subsets comprising a peripheral blood graft may impact on the outcome of an allogeneic transplant. Several groups have assessed whether there is any correlation between quantity of CD34 þ cells infused and end points such as time to engraftment, completeness of engraftment (e.g. degree of chimerism) and incidence of GVHD and infectious complications. Higher doses of CD34 þ cells have been associated with faster neutrophil and platelet recovery in both marrow [34] [35] [36] and peripheral blood allogeneic transplants. [37] [38] [39] Although there is no strict relationship between dose of CD34 þ cells and time to count recovery, most analyses establish a threshold of 2-3 Â 10 6 CD34 þ cells/kg above which time to engraftment is shortened by a few days. Infusion of fewer than 2 Â 10 6 CD34 þ cells/kg may be associated with a higher risk of graft failure, although as so few patients receive doses lower than this, an absolute minimum threshold is not clearly established. This threshold also may be highly dependent on the type and degree of HLA matching between donor and recipient.
CD34 þ cell dose may impact upon the rate of GVHD as well. Higher cell dose was associated with more acute GVHD in one study. 40 Other series have not found a correlation between CD34 þ cells dose and acute GVHD. 37, 41 CD34 þ dose also may appear to correlate with chronic GVHD. Both Przepiorka et al. 40 and Zaucha et al. 37 reported that CD34 doses greater than 8 Â 10 6 /kg are associated with a significant increase in chronic GVHD. Mohty et al. 39 identified a similar CD34 dose (48.3 Â 10 6 / kg), which was associated with a higher risk of extensive chronic GVHD. Data from the Fred Hutchinson Cancer Research Center (FHCRC) show more chronic GVHD with doses 410 Â 10 6 /kg. 42 However, in two studies of patients undergoing non-myeloablative allogeneic PBSC transplants, CD34 dose did not correlate with chronic GVHD. 41, 43 These studies raise the issue of whether CD34 doses given to recipients of HLA-matched sibling or unrelated donor transplants should be 'capped' at some maximum dose. To date, there is no consensus regarding this matter and practices vary widely.
Whether CD34 dose impacts overall survival in recipients of PBSCs is unclear. The FHCRC data suggest that survival is adversely impacted by low (o7) and high (410) CD34 dose, but only in unrelated donor transplant recipients. 44 In patients with leukemia undergoing an unrelated transplant, a marrow cell dose above the median translated into improved survival. 45 Higher CD34 dose may also be associated with better survival in the related transplant setting. 43 In addition to CD34 cells, other cellular subsets in PBSC grafts impact outcome post allogeneic transplantation, although results vary between available series. Baron et al. 41 investigated the affect of graft cell subsets on outcomes in unrelated, non-myeloablative PBSC transplants. They found that higher numbers of T cells, monocytes (CD14 þ ) and CD34 þ cells reduced the risk of graft rejection and were associated with higher T cell chimerism at day 28 post transplant. In contrast to other studies, T cell dose did not correlate with the incidence of GVHD. A similar study of graft composition in related, non-myeloablative PBSC transplants found that infusion of higher numbers of natural killer (NK) cells was associated with early T cell chimerism, more B cells were associated with longer progression-free survival, and higher numbers of CD14 þ cells were associated with worse survival. 43 Another study from Stanford found a correlation between higher CD8 þ cell dose and the likelihood of full donor chimerism and freedom from progression in recipients of truly non-myeloablative conditioning. Together, these studies suggest that a change in the distribution of cellular subsets in a peripheral blood graft may impact graft failure, GVHD and even survival post transplant.
Normal donor mobilization with G-CSF: is it both safe and effective?
G-CSF is commonly used at a dose of 10 mg/kg/day subcutaneously to mobilize PBSCs from healthy donors. Mobilization of cells expressing CD34 antigen peaks in the peripheral blood between days 4 and 5 of G-CSF dosing. 46 Thus, leukapheresis is typically commenced on day 4 or 5 of G-CSF treatment and is repeated until a target number of CD34 þ cells are collected (usuallyX4 Â 10 6 /kg). Compared with the graft composition of bone marrow harvests, G-CSF mobilized products contain three to fourfold higher CD34 þ doses and roughly a 10-to 20-fold increase in CD3 þ T cells. 47 Although many factors including the patient's age, diagnosis and amount of prior therapy have been shown to predict the likelihood of collecting a sufficient number of autologous repopulating cells, factors affecting the capacity of normal donors to mobilize CD34 þ cells following G-CSF are less well established. Reports have indicated in some cases wide interindividual variation among normal subjects given G-CSF for PBSC mobilization. [48] [49] [50] In an IBMTR/EBMT analysis, 60% of donors required more than one leukapheresis procedure to collect the target number of CD34 þ cells, and 15% required three or more. 51 de la Rubia et al. 52 evaluated 261 donors and identified donor age 438 years and use of a single rather than multiple daily G-CSF doses as factors associated with a low CD34 yield. Suzuya et al. 53 and Lysak et al. 54 also found increased age to be a negative predictor for successful mobilization. Another study found that donors with higher baseline peripheral blood CD34 þ cell levels before G-CSF mobilized better than those with lower levels. Thus, donor age, steady-state CD34 level, and both the total dose and schedule of G-CSF may impact CD34 þ cell mobilization.
G-CSF-based PBSC mobilization is generally well tolerated, and essentially all donors complete the mobilization and collection procedures. However, retrospective and prospective studies have identified transient, but not insignificant, morbidities experienced by G-CSF mobilized donors. The most common symptoms are bone pain, headache, fatigue, and nausea, and the incidence of pain and anxiety are similar to that observed with bone marrow donation. [55] [56] [57] [58] [59] In a retrospective analysis of 41300 donors registered with the International Bone Marrow Transplant Registry (IBMTR) or European Blood and Marrow Transplant Group (EBMT), the rate of serious complications from G-CSF mobilization and PBSC collection was 1.1%, as compared with 0.5% following bone marrow collection. 51 Many of these complications were associated with central venous catheters, which were inserted in 20% of donors.
Rare but serious side effects of G-CSF in normal donors
More serious side effects, although rare, nonetheless can occur and represent a major issue when they affect normal individuals. Stroncek et al. 60 reported that 19 of 20 adult allogeneic blood donors given G-CSF 10 mg/kg/day had transient increases in spleen length by an average of 17%. A prospective trial published by Platzbecker et al. 61 in 91 healthy allogeneic donors treated with G-CSF 7.5 mg/kg/ day for 5 days evaluated changes in spleen size using serial ultrasound examinations. Donors exhibited a mean 110% transient increase in spleen length; 20% had a 1.9 cm increase in length and 0.9 cm increase in spleen thickness. A similar study design communicated by Stroncek et al. 62 in 18 healthy subjects given G-CSF 10 mg/kg/day for 5 days revealed a transient mean enlargement of spleen length from 10.7 to 12.1 cm that returned to baseline 10 days after completion of apheresis. Falzetti et al. 63 reported the development of splenomegaly and spontaneous splenic rupture in a 33-year-old male allogeneic blood stem cell donor given G-CSF 16 mg/kg/day for 6 days. He recovered fully after an emergency splenectomy that revealed a 445 g spleen and a capsular tear with massive extra-medullary myelopoiesis. Becker et al. 64 reported a 22-year-old man who donated bone marrow for a first cousin and 4 months later was mobilized with G-CSF 10 mg/kg/day for 6 days as a planned blood progenitor cell collection for relapse. Four days after completion of collection he underwent an emergency splenectomy for spontaneous splenic rupture. G-CSF therapy was not unequivocally the etiology as the donor has serologic findings consistent with convalescence after Epstein-Barr infection. Kro¨ger et al. 65 retrospectively reviewed data obtained from 90 healthy allogeneic donors given G-CSF 5 or 8 mg/kg twice daily. One young subject had a non-fatal traumatic splenic rupture after 5 days of the G-CSF 5 mg/kg twice daily dosing, but this serious adverse event fully resolved without surgical intervention. Dincer et al. 66 reported a-43 year-old man who received the same treatment, experienced a spontaneous splenic rupture on the fifth day of therapy that resolved without surgical intervention. Finally, Balaguer et al. 67 reported a case of a 51-year-old man who developed spontaneous splenic rupture after G-CSF treatment for stem cell mobilization for his HLA-identical sibling; he fully recovered after undergoing an emergency splenectomy. The Spanish National Donor Registry reported this case to be the only such occurrence in 1240 registered PBSC donors. 68 Currently, a trial examining the use of long-acting G-CSF (pegylated filgrastim) in normal allogeneic donors is underway that also prospectively evaluates change in spleen size.
Another potentially serious toxicity may be related to the procoagulant effects of G-CSF and include the risk of precipitating a myocardial infarction or causing cerebral ischemia in high-risk individuals. Both adverse events have been reported and therefore all donors treated with G-CSF should be carefully screened for any history of coronary artery or cerebrovascular disease. [69] [70] [71] [72] Owing to its potential to precipitate acute sickle crisis, G-CSF is contraindicated in patients with sickle cell disease; further, in donors with sickle cell trait, G-CSF has been associated with precipitation of sickle crisis. [73] [74] [75] Patients with underlying autoimmune disease have been treated with G-CSF alone to mobilize cells before planned autologous transplantation. In this setting, its use has been associated with flares of disease in patients with rheumatoid arthritis, systemic lupus erythematosis and multiple sclerosis. [75] [76] [77] [78] [79] Therefore, its use in donors with these disorders also is not recommended.
Even short-term stimulation by G-CSF initiates the cell cycle in at least a fraction of primitive hematopoietic cells. 80 The effects of short-term G-CSF stimulation on genomic stability or chromatin remodeling are unclear. [81] [82] [83] A few studies raise concern that even short-term G-CSF treatment may affect genomic stability. 81, 82 The long-term ramifications of these changes, if any, are unknown and concerns remain largely speculative. That said, there has always been a theoretical concern that exogenous stimulation of hematopoiesis in a first-degree relative of a patient with a hematopoietic malignancy, particularly acute myeloid leukemia, may put the donor at risk for later development of leukemia. In fact, acute leukemia has been noted in G-CSF-stimulated siblings, including two cases of acute myeloid leukemia (AML) occurring 5-6 years after G-CSF administration to mobilize cells for transplant into recipients with AML. 84, 85 Given that the cases of leukemia may have occurred by chance and there is a higher risk of leukemia in first-degree relatives of patients with acute leukemia, the role that G-CSF short-term administration may have played in these cases is speculative. [86] [87] [88] Clearly such occurrences raise concern and justify the call for continued long-term follow-up of G-CSF-stimulated donors, as has been advocated by others. 51, 75, 84, 89 Although beyond the scope of this review, the use of G-CSF in pediatric siblings donating for individuals with malignant or non-malignant disorders also raises concern as to the long-term impact of this maneuver on the health in a young individual. 89 Further, this concern raises several ethical issues related to obtaining both parental consent and assent of the adolescent donor. Others have discussed this issue in detail. 89 In summary, collection of G-CSF-mobilized blood is associated with morbidity comparable to that experienced after bone marrow donation, and many donors must undergo more than one leukapheresis procedure. 56, 75 Donors may benefit from new mobilization strategies that minimize exposure to G-CSF injections and reduce the number of leukapheresis sessions. In addition, recipient outcomes could be improved with grafts that provide faster count recovery or that reduce the incidence of GVHD.
Donor mobilization with GM-CSF: it works but is it reliable?
Although many other cytokines have been investigated for autologous stem cell mobilization, [90] [91] [92] lack of efficacy or potential toxicity has prevented their wide-spread use. Other than G-CSF, only GM-CSF has been commercially approved for stem cell mobilization in the United States. Randomized studies have demonstrated that G-CSF þ GM-CSF is not more effective than G-CSF alone, 93, 94 and CD34 þ cell yield is higher after mobilization with single agent G-CSF than with GM-CSF. [95] [96] [97] However, dramatic differences in the graft content after GM-CSF mobilization have suggested that GM-CSF mobilized products may affect the development of GVHD.
One group performed a retrospective analysis of 166 HLA-matched sibling donors given G-CSF alone (N ¼ 65), GM-CSF alone (N ¼ 10 at 10 mg/kg and N ¼ 21 at 15 mg/ kg), or both G-CSF and GM-CSF (N ¼ 70) as a mobilization strategy. They noted important differences in graft compositions and clinical outcomes with the three approaches. 98 Grafts obtained after GM-CSF versus G-CSF þ GM-CSF mobilization contained significantly fewer T cells and NK cells (Table 1) . GM-CSF (10 mg/kg/day) alone produced an adequate number of CD34 þ cells in only eight of 10 donors who also required more leukapheresis procedures than those given G-CSF. A higher dose of GM-CSF (15 mg/kg/day) mobilized more CD34 þ cells but was associated with unacceptable toxicity, including grade 3 fever and hypotension in two patients. Interestingly, only 13% of GM-CSF-mobilized graft recipients experienced acute GVHD (none with grades 3 and 4), significantly reduced compared with 49% with G-CSF-mobilized grafts and 69% with G-CSF/GM-CSF-mobilized grafts (Po0.001). PBSC grafts mobilized with GM-CSF may reduce the risk of acute GVHD after HLA-matched PBSC transplantation at a cost of inadequate CD34 þ mobilization. However, the higher doses required to mobilize adequate CD34 þ cells cause greater toxicity and therefore dampen enthusiasm for exploring this agent further in normal donors. AMD3100: targeting the key regulator of hematopoietic stem cell trafficking AMD3100, a promising new agent for the mobilization of stem cells, is a bicyclam derivative that reversibly inhibits the binding of SDF-1 to its receptor CXCR4, promoting mobilization of CD34 þ cells to the peripheral circulation. 99 Preclinical work in murine, canine and non-human primate systems have suggested that AMD3100 alone can rapidly mobilize hematopoietic cells possessing both shortand long-term repopulating capacity. [100] [101] [102] Broxmeyer et al. 101 compared the SCID repopulating capacity (SRC) of human hematopoietic cells mobilized by G-CSF with AMD3100 mobilized cells and found a greater frequency of SRC among the population of cells mobilized by AMD3100. Later, Burroughs et al.
100 used a well-described canine allogeneic transplant model to demonstrate the long-term repopulating capacity of cells contained within apheresis products collected from donors treated just 6 h previously with a single injection of AMD3100. The cells were able to maintain trilineage hematopoiesis and promote a full donor chimeric state in three lethally irradiated recipients for up to 32 months. Further, Larochelle et al. 102 collected CD34 þ cells from rhesus macaques mobilized following either 5 days of G-CSF or a single dose of AMD3100. The CD34 þ cells were retrovirally marked with the neomycin resistance gene (NeoR) and subsequently transplanted back into autologous recipients following myeloablative conditioning. AMD3100-mobilized cells engrafted gene marked myeloid and lymphoid cells up to 32 months following transplantation. The AMD3100-mobilized CD34 þ population contained a higher frequency of cells in the G1 phase of the cell cycle, with greater expression of CXCR4 and VLA-4 compared with G-CSF-mobilized cells. Together, these preclinical Table 1 Comparison of allografts mobilized and collected from normal donors using a variety of mobilizing agents: Washington University experience 
98,109
Donor stem cell mobilization AF Cashen et al studies suggest fundamental differences in the characteristics of HSC/HPC mobilized by AMD3100 versus G-CSF and set the stage for initial clinical trials to evaluate the effects of transplanting cells mobilized by AMD3100 into humans. Recently, the repopulating capacity of CD34 þ cells mobilized with AMD3100 was more fully characterized. Using leukapheresis products collected from seven sibling donors treated on a trial of AMD3100 mobilization, Hess et al. 103 compared the NOD/SCID repopulating activity of the total mononuclear cell (MNC) fraction and of purified CD34 þ cells mobilized from each donor by AMD3100 or G-CSF. Comparison of paired samples from each patient eliminated inter-patient variability in the analysis. Bone marrow repopulation was found to be threefold greater with AMD3100-mobilized MNCs than with G-CSFmobilized MNCs. Purified AMD3100-mobilized CD34 þ cells also possessed strong repopulating capacity, which was still superior to that of G-CSF-mobilized CD34 þ cells in most patients. These results demonstrate potentially important qualitative differences in the repopulating capacity of grafts mobilized by the two agents.
Initial clinical trials of AMD3100 in healthy volunteers demonstrated a more than 10-fold increase in PBSCs beginning 1 h and peaking 9 h after subcutaneous injection of AMD3100. 104 The addition of AMD3100 to G-CSF results in even greater increases in circulating CD34 þ cells.
105 AMD3100 can mobilize PBSCs in patients who have received prior chemotherapy as well. In a Phase I study, patients with multiple myeloma or non-Hodgkin lymphoma (NHL) had a sevenfold increase in circulating CD34 þ cells 6 h after a single dose of AMD3100 (240 mg/kg).
106
In autologous stem cell collection trials, AMD3100 (160-240 mg/kg) has been added to G-CSF on day 4, 6-12 h before pheresis. Flomenberg et al. 107 reported use of this combination in 25 multiple myeloma and non-Hodgkin lymphoma patients who each underwent two mobilizations, one using G-CSF alone and the other with G-CSF þ AMD3100. Given as either the first or second mobilization regimen, G-CSF þ AMD3100 mobilized more CD34 þ cells per leukapheresis. In addition, patients underwent fewer leukaphereses, and more patients attained the target collection of 5 Â 10 6 CD34 þ cells/kg with the combination of G-CSF and AMD3100. Eighteen of 19 patients undergoing transplant with the G-CSF/AMD3100-mobilized product had early, stable engraftment. Mobilization with G-CSF þ AMD3100 is also efficacious in patients with Hodgkin disease (HD). Cashen et al. 108 reported on 10 HD patients mobilized with AMD3100 and G-CSF. All patients collected the minimum 2 Â 10 6 CD34 þ cells/kg, and 60% of patients collected more than 5 Â 10 6 CD34 þ cells/kg, a significantly higher percentage than a historic control group mobilized with G-CSF alone. All eight patients who had been transplanted with AMD3100 þ G-CSFmobilized grafts had stable engraftment.
Given these promising results in autologous mobilization, AMD3100 is now being investigated for stem cell mobilization and transplantation from healthy donors. Devine et al. 109 have reported the preliminary results of a pilot study evaluating the safety and efficacy of AMD3100 mobilization and transplantation in HLAmatched sibling donors. Eleven donors were mobilized with AMD3100 (240 mg/kg) subcutaneously, followed 4 h later by leukapheresis. The next week, each donor underwent a second mobilization using G-CSF (10 mg/kg/day). Ten of 11 patients met the goal collection of X2.0 Â 10 6 CD34 þ cells/kg after AMD3100 treatment, six patients with a single leukapheresis procedure. No significant toxicities from AMD3100 were observed. The AMD3100-mobilized grafts contained significantly fewer CD34 þ cells (2.6 vs 4.1 Â 10 6 /kg, P ¼ 0.05) and more CD3 þ cells (4.4 vs 1.5 Â 10 8 /kg, P ¼ 0.04) compared with the G-CSF-mobilized grafts (Table 1) . Allogeneic transplants have been performed in eight patients using an AMD3100 mobilized graft, and engraftment kinetics was similar to that from G-CSF-mobilized allografts. Thirteen percent of patients developed grades 2-4 acute GVHD, and two of six evaluable patients (33%) developed chronic GVHD. Therefore, despite the infusion of higher T cell doses, there was no appreciable increase in GVHD in comparison to G-CSF-mobilized grafts.
Future directions
Although G-CSF is an effective agent for the mobilization of stem cells from normal donors, such altruistic individuals could benefit from new mobilizing strategies, which are more effective and/or less toxic. The agents currently in use to mobilize stem cells in donors have both unique and overlapping toxicities (Table 2) . Each has its own potential advantages and disadvantages (Table 3) . Notably, each product results in the mobilization of an allograft with unique cellular compositions that may alter the likelihood of graft failure, GVHD, immune reconstitution and possibly relapse. The search for new mobilizing agents currently is driven by preclinical research, which is elucidating the mechanisms of stem cell localization within the bone marrow and mobilization in response to cytokine signals. As our understanding of the interactions between stem cells and the bone marrow microenvironment 16 Unfortunately, this agent exerts pleiotropic effects on neutrophils and other white blood cells possibly resulting in undesirable toxicities.
The SDF-1/CXCR4 inhibitor AMD3100 has demonstrated efficacy for the mobilization of autologous stem cells in combination with G-CSF for patients with nonHodgkin lymphoma (NHL), multiple myeloma and HD. [106] [107] [108] However, its role in mobilization of normal donors remains to be defined. In the limited clinical experience with AMD3100 for mobilization of donor PBSCs, single-agent AMD3100 produces a lower CD34 þ stem cell yield than G-CSF. 109 However, the yield may improve if the interval between dosing and apheresis is optimized to take advantage of the period of maximum circulating CD34 þ cells. Studies in normal donors administered AMD3100 8-10 h before commencing apheresis are therefore warranted. Also, the improved repopulating capacity of the AMD3100-mobilized graft or clinically important alterations in the graft content may compensate for the lower CD34 þ cell dose. Certainly, further studies to better define the efficacy of AMD3100 for donor mobilization are needed.
In addition to causing CD34 þ cell mobilization by its indirect effects on CXCR4/SDF-1, G-CSF has pleiotropic effects on other important allograft constituents including T-, B-, NK-and dendritic cells.
5,110-116 G-CSF administration has been associated with a polarization of T cells to a Th2 phenotype. 5, 110, 112 G-CSF effects circulating monocytes, leading to an increase in IL-10 secretion. Also, G-CSF administration may induce a plasmacytoid differentiation effect on donor dendritic cells. 5, [110] [111] [112] 114 Together, these immunomodulatory effects of G-CSF have been cited to explain the observation that rates of acute GVHD are not substantially different using mobilized cells compared with bone marrow despite the transplantation of about 10-fold greater numbers of T cells. In an effort to further understand and possibly exploit these immunomodulatory effects, G-CSF analogues have recently been studied to determine their influence on stem cell mobilization, GVHD and graft-versus-leukemia (GVL). Pegylated filgrastim (Neulasta; Amgen, Thousand Oaks, CA, USA) has a much longer half-life compared with native filgrastim, and a single dose results in the mobilization of sufficient numbers of CD34 þ cells to promote engraftment in allogeneic recipients following myeloablative conditioning. 117 One study in HLA-identical sibling donors suggested a 12 mg dose may be superior to 6 mg in terms of CD34 þ cell dose mobilized. 117 The allografts mobilized by pegfilgrastim appeared to result in similar kinetics of engraftment as well as comparable rates of GVHD compared with native filgrastim. The kinetics of mobilization following a single dose of pegylated filgrastim were roughly the same as that observed following daily G-CSF administration with peak CD34 þ cell mobilization occurring by days 5-6. Recently, a chimeric molecule containing ligands for both G-CSF and Flt-3 has been shown to limit GVHD while retaining the capacity to induce GVL in murine models, possibly through the expansion of regulatory NK/T-type cells. 118, 119 Further work is needed to validate these effects. It is unclear whether chimeric molecules will be further developed for clinical use, particularly in volunteer donors, because of concerns regarding enhanced toxicity associated with stimulating multiple receptors.
Osteoblasts, which line the trabecular bone surfaces forming the HSC bone marrow niche, represent a novel target for stem cell therapies. 120 Although the precise role of osteoblasts in blood development is unknown, they secrete a number of cytokines with hematopoietic activity. 121 Parathyroid hormone (PTH) stimulates trabecular bone growth by activating PTH receptors on osteoblasts, thereby increasing the HSC niche. Calvi et al. 122 demonstrated that osteoblasts with constitutively active PTH receptors support an increased number of HSCs, an effect which occurs via Notch activation. In addition, wild-type mice had an increase in bone marrow HSCs after daily treatment with PTH. Ballen et al. 123 treated 12 lymphoma patients who had previously failed stem cell mobilization with PTH (40, 60, 80 or 100 mg/day for 14 days) and G-CSF (10 mg/kg/day for 4 days). The four patients who proceeded to apheresis collected a median CD34 þ dose of 2.2 Â 10 6 /kg. These studies could yield important initial data regarding the possibility of in vivo stem cell expansion, although it will be difficult to discern based on the trial design unless the differences between the first and second mobilizations are striking. The trial rationale was based on murine experiments where PTH was given for 28 days. Clearly, this duration of administration is impractical in patients with cancer and a shorter duration was chosen. Although these studies may be justified in patients who might derive benefit from high-dose chemotherapy, given the amount of time required to induce Jagged (a ligand for Notch) expression on osteoblasts and the potential toxicity associated with PTH (e.g. hypercalcemia) as well as other unknown long-term side effects, this agent is unlikely to be useful for stimulating mobilization in normal donors. Larger clinical trials are needed to determine whether PTH or other bone-stimulating agents can improve stem cell collection in autologous or normal donors. The role other accessory cells contained within an allograft (e.g. mesenchymal cells, endothelial precursor cells) may play in mitigating GVHD, enhancing engraftment or in stimulating angiogenesis in the post transplant setting has recently interested investigators. Although a typical bone marrow allograft may contain a substantial number of stromal cells, the effect of these cells on clinical outcomes following transplantation is dubious. Donor stromal cells do not appear under most circumstances to make any substantial contribution to engraftment, nor do they survive within the host microenvironment for any significant length of time. [124] [125] [126] [127] [128] [129] Whether stromal cells can be mobilized into the circulation by G-CSF, AMD3100 or any stimulus for that matter, remains largely speculative. It is unlikely that substantially large numbers of stromal cells or so called mesenchymal stem cells can be mobilized by current techniques to make a substantial impact on engraftment, GVHD, GVL or any other clinical end point without some type of ex vivo expansion before transplantation.
Recent interest has also focused on the capacity of G-CSF to stimulate the egress of circulating angiogenic cells (CAC) or endothelial precursors cells (EPC) capable of stimulating angiogenesis. Given the potential impact of this phenomenon in patients suffering from myocardial ischemia or peripheral vascular disease, G-CSF has been studied in the post-myocardial infarction setting. Although it is clear that G-CSF mobilizes EPC and CAC, its impact on modifying post-infarct myocardial function has been minimal in most clinical trials reported to date. [130] [131] [132] [133] Our group has recently demonstrated that treatment of normal donors with both G-CSF and AMD3100 can result in an 8-to 21-fold increase in the number of circulating EPC. 134 Additionally, both agents stimulate the mobilization of a discrete population of circulating monocytes in humans, termed circulating angiogenic cells (CAC), which possess the capacity to hasten recovery from surgically induced hindlimb ischemia in a NOD/SCID xenograft model. 134 Interestingly, AMD3100 causes the mobilization of CAC within 4 h of a single dose in contrast to the 5 days of G-CSF treatment required to mobilize roughly similar numbers of CAC. This raises the intriguing possibility that AMD3100 may be useful for mobilizing angiogenic cells in an acute setting where myocardial injury is ongoing. 135 The increased use of mobilized peripheral blood as the stem cell source for related and unrelated donor transplants has challenged the transplant community to find better agents for stem cell mobilization. Ongoing preclinical research promises to provide new targets for agents that can improve the efficiency of stem cell collection. In addition, further exploration of the currently available mobilizing agents, including AMD3100, may advance the field beyond single-agent G-CSF.
